Observational Study of Conjunctivitis in the Setting of DUPIXENT® Treatment for Atopic Dermatitis
Completed · NCT04287608
Conditions: Conjunctivitis, Atopic Dermatitis
At a glance
- Research payments reported, 2025
- $4,143
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 50
About the trial
- Sponsor
- Regeneron Pharmaceuticals (with Sanofi)
- Tested
- dupilumab (drug)
- Dates
- Started 2021-03-10; completion 2023-03-29
- Results posted
- Not yet
The primary objective of the study is to characterize the clinical phenotype(s) of DUPIXENT®-associated conjunctivitis events. The secondary objectives of the study are to characterize the course of conjunctivitis events during the observation period and collect and assess data on treatment for conjunctivitis events and its effectiveness.
From ClinicalTrials.gov, last updated 2023-04-28. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Regeneron Pharmaceuticals, Inc. reported $4,143 in research payments for this study in 2025 (4 payments).
Products named: Dupixent
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- $2,944
- Mount Sinai School of Medicine $1,199
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.